Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02554396 | Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia | PHASE2 | COMPLETED | 20 | — | — | Sep 1, 2015 | Nov 1, 2015 | Oct 23, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| PRX-100 | EXPERIMENTAL | PRX-100 ophthalmic solution |
| Placebo | PLACEBO_COMPARATOR | saline solution |
| Name | Type | Description |
|---|---|---|
| PRX-100 | DRUG | ophthalmic solution |
| Placebo | DRUG | saline ophthalmic solution |
Inclusion Criteria: 1. be 45-59 years of age of either sex and any race or ethnicity; 2. be able and willing to provide written informed consent and sign HIPAA form prior to any study procedure being performed; 3. be able and willing to follow all instructions and attend all study visits; 4. have a...